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Abstract
Nasal colonization by the pathogen Staphylococcus aureus is a risk factor for subsequent infection. Loss of function
mutations in the gene encoding the virulence regulator Rsp are associated with the transition of S. aureus from a colonizing
isolate to one that causes bacteraemia. Here, we report the identification of several novel activity-altering mutations in rsp
detected in clinical isolates, including for the first time, mutations that enhance agr operon activity. We assessed how these
mutations affected infection-relevant phenotypes and found loss and enhancement of function mutations to have contrasting
effects on S. aureus survival in blood and antibiotic susceptibility. These findings add to the growing body of evidence that
suggests S. aureus ‘trades off’ virulence for the acquisition of traits that benefit survival in the host, and indicates that
infection severity and treatment options can be significantly affected by mutations in the virulence regulator rsp.
The Gram-positive bacterium Staphylococcus aureus is a
major pathogen that causes a range of human infections
[1]. An effective immune response supports the rapid res-
olution of superficial skin and soft tissue infections
caused by S. aureus, often without the need for treatment.
However, entry into the bloodstream can lead to the met-
astatic spread of S. aureus and the establishment of more
severe infections at distal sites, some of which can be dif-
ficult to treat [1, 2].
Although capable of causing infections, S. aureus exists
primarily as a commensal organism, colonizing the ante-
rior nares of an estimated ~30% of the population. Nasal
carriage is a significant risk factor for infection [3–5], and
several genetic analyses have confirmed that infecting
strains are typically those colonizing the individual, with
only a few genetic alterations [6–9]. One longitudinal
study identified a protein-truncating mutation in an
AraC-type transcription regulator Rsp (repressor of sur-
face proteins) that preceded, and was implicated in the
development of, S. aureus bacteraemia [7]. Subsequently,
a single mutation resulting in the A204P substitution in
the AraC DNA-binding domain of Rsp was found to be
the only difference between carriage and bacteraemia iso-
lates from another infected patient [8, 9].
Rsp is a highly conserved DNA-binding regulator of the acces-
sory gene regulator (agr) operon in S. aureus that regulates the
expression of nearly all virulence factors in a cell density-
dependent manner [10, 11]. Despite this important role in vir-
ulence factor expression, agr dysfunctional strains are often
isolated from bloodstream infections, and have been associ-
ated with increased duration of and mortality attributed to
S. aureus bacteraemia [12–18]. Given that Rsp is a regulator of
the agr operon [10], and loss of function mutations in rsp
have previously been associated with S. aureus bacteraemia
[7, 9], we aimed to investigate the phenotypic consequences
and clinical implications of naturally occurring rsp mutations
in methicillin-resistant S. aureus (MRSA). We interrogated
1429 published whole genome sequences of clinical isolates
belonging to sequence type 22 (ST22) [19–24], a globally suc-
cessful MRSA clone, for mutations in rsp as previously
described [23]. To exclude intra-species polymorphisms in rsp
from our analysis, rsp from the ST22 MRSA reference
sequence (strain HO 5906 0412) [23] was compared to all
complete S. aureus genomes (212) available on the NCBI
Genome database. This revealed a high level of sequence con-
servation (99% identity) and validated the identified non-
synonymous mutations.
Twenty-seven novel substitutions and five truncation muta-
tions in rsp were identified in 39 clinical isolates (Fig. 1a).
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The most common mutation, present in four geographically
distinct clinical isolates, resulted in the D103N amino acid
substitution, preceding the DNA-binding domain. This sub-
stitution was also found in combination with P626L in an
additional isolate. The AraC DNA-binding domain of Rsp
was the site of four mutations including one that resulted in
the A204V substitution, similar to A204P reported previ-
ously [8, 9]. To assess the impact of these mutations on Rsp
function, namely the ability to activate agr operon
expression, an integrated agr-P3-mCherry promoter fusion
construct (P3mCh) was employed and mCherry fluores-
cence quantified relative to optical density at 600 nm over a
16 h period [25]. The 32 identified rsp mutations were intro-
duced into the wild-type pCN34 rsp complementation vec-
tor via site-directed mutagenesis, and wild-type and mutant
plasmids were transformed into the MRSA USA300 strain
JE2 carrying the bursa aurealis transposon in rsp (rsp :: Tn)
[26], following a published protocol [27]. Sequence analysis
Fig. 1. Identification and investigation of the effect of rsp mutations on agr expression and haemolysin production. (a) Schematic
representation of Rsp with the AraC DNA-binding domain (DBD) indicated. Arrows show sites of truncation events while points repre-
sent individual amino acid substitutions, coloured red, green or white to indicate ‘loss of function’, ‘enhancement of function’ and non-
altering mutations in rsp, respectively. Growth-normalized agr operon activity (b) and haemolysin production (d) of strains at the 16 h
time point are expressed relative to the wild-type reporter strain JE2 P3mCh pCN34. Loss of function, enhancement of function and
non-altering mutations are coloured red, green and white, respectively. For brevity, transposon disruption by bursa aurealis is noted as
’::Tn’. agr operon expression (c) and haemolysin production (e) relative to the wild-type reporter strain of loss of function and enhance-
ment of function rsp mutations. Each point represents the mean of three independent experiments conducted for each rsp mutant. The
median is represented by the horizontal line, with box and whiskers showing the interquartile range and range. P-values were
obtained by one-way ANOVA compared to the wild-type with Dunnett’s post hoc correction (**** P0.0001).
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revealed that Rsp from the ST22 reference sequence and
MRSA USA300 JE2 differed at only a single amino acid, res-
idue 75. In ST22 S. aureus HO 5906 0412 residue 75 is a
phenylalanine, while in JE2 a tyrosine. As these amino acids
differ by only a hydroxyl group [28], we deemed this muta-
tion unlikely to have a significant effect on Rsp function.
The presence of the bursa aurealis transposon rendered
S. aureus strains erythromycin resistant and hence were
grown in tryptic soy broth (TSB) supplemented with 10 µg
erythromycin ml 1 [26]. Maintenance of pCN34 was
achieved via the addition of 90 µg kanamycin ml 1 [29].
Transposon mutants of rsp (rsp :: Tn) and the master regula-
tor of the agr operon agrA (agrA :: Tn) [26], along with their
respective pCN34-complemented strains [30], performed as
experimental controls to validate our findings.
As shown in Fig. 1(b), expression from agr-P3 of the four
control strains and 32 rsp mutants was compared to the
wild-type reporter strain JE2 P3mCh carrying empty
pCN34 (JE2 P3mCh pCN34) after 16 h of growth in TSB at
37

C, when agr-P3 expression plateaued. As expected, dis-
ruption of agrA, the master regulator of the agr operon by
transposon insertion, led to a 99% reduction in agr P3
expression, which returned to wild-type levels upon com-
plementation [30]. Similarly, the rsp :: Tn strain showed a
38% reduction in agr-P3 expression, which was restored by
complementation. Eleven of the 32 rsp mutants exhibited a
significant reduction in agr-P3 expression, 75% of the
wild-type strain (Fig. 1c). These mutations were therefore
referred to as ‘loss of function’ and included the five trunca-
tion mutations in Rsp and the A204V substitution. Muta-
tion of residue 204 in the AraC DNA-binding domain from
alanine to proline has previously been predicted to abrogate
Rsp function [8, 9], further validating our findings. In addi-
tion, eight ‘enhancement of function’ mutations were found
to significantly increase agr-P3 expression by 120% of
wild-type (Fig. 1c), including that conferring the most com-
mon substitution in the collection, D103N. The elevated
agr-P3 levels exhibited by the double-substitution D103N/
P626L were attributed to the presence of the D103N substi-
tution, as P626L per se did not affect agr-P3 expression
(Fig. 1b).
To confirm that the observed alterations in agr-P3 expres-
sion were directly affecting agr-dependent target gene
expression, agr-dependent haemolysin production was
quantified as described previously [31]. Disruption of agrA
and rsp by transposon insertion resulted in 92 and 50%
reductions in haemolysin production compared to the wild-
type strain, respectively (Fig. 1d). Haemolysin production
by both strains was returned to wild-type levels upon com-
plementation. Activity-altering mutations in rsp that
reduced or enhanced agr-P3 expression correspondingly
affected haemolysin production (Fig. 1d, e), thus phenotypi-
cally validating the results obtained via the agr-P3-mCherry
promoter fusion construct.
Dysfunction of both agr and rsp have been associated with
S. aureus bacteraemia [7, 13, 16–18]. Therefore, an ex vivo
whole human blood model was employed to assess the effect
of activity-altering mutations in rsp on S. aureus survival
and resistance to killing by immune components. Assays
were performed as described previously [32], using freshly
drawn whole blood from four independent healthy human
donors. In line with previous findings [32], disruption of
the master regulator of the agr operon, agrA, led to a >ten-
fold decrease in S. aureus survival compared to the wild-
type strain following 6 h incubation in whole human blood
(Fig. 2a, b). Although transposon disruption of rsp resulted
in a reduction in agr expression (Fig. 1), no corresponding
decrease in S. aureus survival was observed (Fig. 2a, b). Sim-
ilarly, as previously reported for the truncation and A204P
substitution mutants of Rsp [9], loss of function mutations
in rsp did not significantly alter S. aureus survival in blood
(Fig. 2c). Conversely, rsp mutations that enhanced agr
operon expression (Fig. 1c) were found to significantly
improve S. aureus survival following 6 h incubation in blood
(Fig. 2c).
The findings of the ex vivo whole human blood model are in
support of published accounts that suggest agr-regulated
virulence factors involved in immune evasion and host cell
destruction are required for S. aureus survival in human
blood [32, 33]. Moreover, the results reported here indicate
that there is a requirement for a basal level of agr expression
for S. aureus survival in the bloodstream. We hypothesize
that below this level, agr-dependent immune evasion and
virulence factors are not able to effectively defend S. aureus
against host immune attack [34]. While the identification of
rsp mutants that increased both agr-P3 expression (Fig. 1b,
c) and S. aureus survival in whole human blood at 6 h
(Fig. 2b, c) suggests that an increase in agr expression
favours survival in blood, we cannot discount the possibility
that these rsp mutants affect the expression of agr-indepen-
dent factors that may influence S. aureus survival in the
bloodstream.
In addition to killing by the host immune system, antibi-
otics present an additional threat to S. aureus in the
bloodstream [2, 35]. Increased tolerance to vancomycin
and daptomycin, two first-line therapies for MRSA bac-
teraemia, has been associated with dysfunction of the agr
operon [36–41]. We therefore determined whether loss
and/or enhancement of function mutations in rsp affected
the minimal inhibitory concentration (MIC) of vancomy-
cin and/or daptomycin using the broth microdilution
approach [42]. As shown in Table 1, the wild-type strain
JE2 P3mCh pCN34 exhibited MICs for vancomycin and
daptomycin in line with published reports [41, 42].
Despite an association between agr dysfunction and an
increased tolerance to vancomycin being widely reported
[36–40], disruption of agrA by transposon insertion did
not alter the vancomycin MIC, as reported previously
[41]. A twofold increase in the daptomycin MIC was,
however, observed for the agrA transposon mutant, which
was returned to wild-type levels upon complementation.
Similarly, disruption of rsp by transposon insertion or
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loss of function mutation led to a twofold, complement-
able increase in the MIC of both first-line antibiotics.
Mutations in rsp that enhanced agr operon expression
showed an inconsistent effect on vancomycin MIC, but
did not affect daptomycin MIC.
As the increase in vancomycin MIC displayed by the rsp
transposon mutant and loss of function mutants is unlikely
to be due to the corresponding reduction in agr expression,
we hypothesize that it may be due to alterations in cell wall
physiology. A thickening of the S. aureus cell wall has previ-
ously been associated with an increased tolerance to vanco-
mycin [43–45], and Rsp has been shown to regulate the
expression of several genes involved in cell wall homeostasis
[10]. We therefore hypothesize that Rsp regulates cell wall
physiology in an agr-independent manner, and thus disrup-
tion and loss of function mutation in rsp increases tolerance
to vancomycin.
The effect of rsp mutation on the killing kinetics of S. aureus
by daptomycin was investigated in greater detail via a 6 h
killing assay performed in Mueller–Hinton Broth (MHB)
supplemented with Ca2+ (50 µg ml 1) and Mg2+ (10 µg
ml 1) [41, 42]. Daptomycin was used at a concentration of
5 µg ml 1, 10x the wild-type MIC (Table 1). Disruption of
agrA led to an initial period of killing by daptomycin, with
percentage survival comparable to the wild-type strain at
the 2 h time point. This was followed by recovery to tenfold
greater survival than wild-type at the 6 h time point (Fig. 2d,
e), in line with previous findings [41]. The initial period of
killing followed by recovery phenotype was also exhibited
by the rsp transposon mutant, that recovered >tenfold than
the wild-type strain at 6 h of incubation with daptomycin
(Fig. 2d, e). Similarly, loss of function mutations in rsp were
found to significantly enhance survival in daptomycin, while
Fig. 2. Effect of activity-altering rsp mutations on S. aureus survival in whole human blood (top) and in the presence of the lipopeptide
antibiotic daptomycin (bottom). Percentage survival of strains in blood (a) and in a supra-MIC concentration of daptomycin (d) over 6 h
is expressed relative to total inoculum at time 0. Percentage survival of rsp mutants following 6 h incubation in blood (b) or daptomycin
(e). Loss of function and enhancement of function mutations are coloured red and green, respectively. For brevity, transposon disrup-
tion by bursa aurealis is noted as ’::Tn’. Percentage survival of loss of function and enhancement of function rsp mutations in blood (c)
and daptomycin (f). Each point represents the mean of four independent experiments conducted for each rsp mutant. The median is
represented by the horizontal line, with box and whiskers showing the interquartile range and range. P-values were obtained by one-
way ANOVA compared to the wild-type with Dunnett’s post hoc correction (*** P0.001, ** P0.01).
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enhancement of function mutations were unable to do so
(Fig. 2f).
Supported by previous findings [41], we hypothesize that loss
of function mutations in rsp reduce agr operon expression
and corresponding agr-dependent phenol-soluble modulin a
(PSMa) production. This favours the sequestration of dapto-
mycin in released phospholipid, preventing it targeting the cell
membrane and inducing cell death. Conversely, enhancement
of function rsp mutations cause an overexpression of agr and
PSMa that compete for released phospholipid, preventing
sequestration of daptomycin for protection.
The virulence regulator Rsp and its substitutions have been
the focus of several recent publications [8–10, 46]. In this
study, we build on this growing body of work by identifying
multiple novel mutations in MRSA clinical isolates, includ-
ing several ‘enhancement of function’ mutations in rsp that
significantly increased expression of the major virulence
regulator agr (Fig. 1c). Three such mutations were found to
precede the AraC DNA-binding domain, resulting in the
D103N, G115E and A103V substitutions (Fig. 1a). Although
unlikely to directly affect Rsp’s interaction with RNA
polymerase and DNA-binding ability – both functions per-
formed by the AraC DNA-binding domain [10, 47] – these
substitutions may alter Rsp’s interaction with other tran-
scription regulatory factors. For example, an AraC Negative
Regulator (ANR) was recently found to bind to the region
preceding the AraC DNA-binding domain of AggR, pre-
venting DNA binding [48, 49]. Therefore, it is plausible that
D103N, G115E and A130V enhancement of function substi-
tutions in Rsp may prevent binding of possible ANRs, ulti-
mately promoting agr-P3 expression.
The effect of novel activity-altering mutations in rsp on clin-
ically relevant phenotypes was investigated further, with
emphasis on phenotypes relevant to S. aureus bacteraemia –
survival in whole human blood and in first-line antibiotics
used in the treatment of MRSA bacteraemia. We discovered
that enhancement of function mutations in rsp, while pro-
moting expression of agr-P3 (Fig. 1c) and survival in whole
human blood (Fig. 2c), did not affect the susceptibility of
S. aureus to vancomycin or daptomycin (Table 1 and
Fig. 2f). Conversely, loss of function mutations in rsp, while
reducing agr-P3 expression (Fig. 1c), did not affect S. aureus
survival in whole human blood (Fig. 2c) but enhanced sur-
vival at a supra-MIC concentration of daptomycin (Fig. 2f).
These findings led us to propose that via a mutation of rsp,
S. aureus can modulate or ‘trade off’ the production of tradi-
tional virulence determinants with contradicting conse-
quences for antibiotic tolerance and its ability to survive
immune attack and cause disease.
The notion that S. aureus compromises or ‘trades off’ its
production of virulence determinants to acquire additional
traits is relatively new, and is in direct conflict with the tra-
ditional paradigm of loss of agr reducing S. aureus virulence
[46, 50]. Low-toxicity S. aureus isolates, including mutants
of agr and rsp, were recently shown to have enhanced fitness
in the presence of human serum compared to high-toxic
isolates [50]. In combination with mathematical modelling,
it was proposed that a high-toxicity state facilitates the
spread and transmission of S. aureus between hosts, while
low toxicity promotes in-host survival. The results of our
study are in line with and augment these findings, leading
us to hypothesize that the low-toxicity state established via
loss of function mutation of rsp would lead to more invasive
infections that are also more difficult to treat with current
therapeutics. This ‘trade-off’ may thus explain the frequent
isolation of agr dysfunctional strains from invasive S. aureus
bacteraemia infections [12–16, 18], and the acquisition of
mutations in rsp leading to S. aureus bacteraemia [7–9].
In summary, the findings of this study, in addition to others
recently published [9, 50], demonstrate that mutations
within rsp can have significant impacts on staphylococcal
toxin production and bacterial survival against the twin
threats of host defences and antibiotics.
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